Paragon Associates & Paragon Associates Ii Joint Venture Dia Medica Therapeutics Inc. Transaction History
Paragon Associates & Paragon Associates Ii Joint Venture
- $40.9 Million
- Q2 2024
A detailed history of Paragon Associates & Paragon Associates Ii Joint Venture transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Paragon Associates & Paragon Associates Ii Joint Venture holds 482,614 shares of DMAC stock, worth $2 Million. This represents 3.48% of its overall portfolio holdings.
Number of Shares
482,614
Previous 500,000
3.48%
Holding current value
$2 Million
Previous $1.39 Million
2.74%
% of portfolio
3.48%
Previous 2.47%
Shares
4 transactions
Others Institutions Holding DMAC
# of Institutions
34Shares Held
3.84MCall Options Held
1.3KPut Options Held
1K-
Vanguard Group Inc Valley Forge, PA1.02MShares$4.22 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$3.48 Million0.01% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.59 Million0.41% of portfolio
-
Geode Capital Management, LLC Boston, MA237KShares$983,0850.0% of portfolio
-
Jacob Asset Management Of New York LLC Hermosa Beach, CA169KShares$700,2290.62% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $110M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...